Drug
Dimethyl
Dimethyl: highest development phase Post-Market, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| dimethyl fumarate NCT02343159 | Post-Market | Multiple Sclerosis |
| Dimethyl fumarate NCT02461069 | Post-Market | Multiple Sclerosis, Relapsing-Remitting |
| dimethyl fumarate NCT01838668 | Phase 3 | Relapsing-Remitting Multiple Sclerosis |
Latest
No recent events.
Follow Dimethyl on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.